Announcement Precision Biologics, Inc. declared in vivo and in vitro efficacy of its novel tumor-specific ADC (PB-vcMMAE-5) in competition against human carcinomas reacting with truncated core 2 O-glycans. The current data for various human cancer types, précising truncated core 2 O-glycans...
Announcement OrsoBio, a leading clinical-level biopharmaceutical company working towards the development of related metabolic disorders and obesity treatments, have showcased the presentation of new preclinical and clinical data at ObesityWeek® 2025 held in Atlanta, Ga, on November 4-7. The com...
Announcement The leading United Therapeutics Corporation has completed its first clinical xenotransplantation in its EXPAND study, using UKidney™ in patients with end-stage renal disease (ESRD). At NYU Langone Health, this successful transplant procedure was performed. The UKidney is an inves...
Announcement Estrella Immunopharma, Inc., a leading clinical-level biopharmaceutical company establishing CD19 and CD22-focused ARTEMIS® T-cell therapies to provide treatment to autoimmune and cancer diseases, declared the completion of its second dose associate in the Phase 1 portion of its S...
Announcement Immunis, Inc., a clinical-level biotech establishing creative stem cell empowered biologics for disease and age-based immune dysregulation, has officially published peer-reviewed research in partnership with Dr Micah Drummond from the University of Utah. The discovery published in obe...
Announcement Forlong Biotechnology, a leading clinical-level biotech company, aims to establish a transitional change in cytokine therapies for extreme unmet needs for a certain patient group proudly declared that the first patient has been dosed in a phase 2 clinical trial investigating FL 115 in ...
Image Credit: Tectonic Therapeutic Announcement The Tectonic Therapeutic Inc. has showcased its successful positive topline results from the phase 1b part B acute hemodynamic clinical trial of TX45. It’s a long reactive Fc-relaxin fusion protein in patients going through group 2 PH-H...
Image Credit: Ferring Pharmaceuticals Announcement Ferring Pharmaceuticals confirmed that three abstracts focusing on ADSTILADRIN will be showcased at the 101st Annual Meeting of the Western Section of the American Urological Association (AUA) in Napa, to be held from November 2 to 6, 2025...
Announcement The bridgeBio Pharma’s in-progress investigational oral small molecule BBP-418, an under-development study to cure a particular form of limb-girdle muscular dystrophy, has entered a late-stage trial. Following this, the new drug application is planned to proceed by the first half...
Announcement The uniqueness of gene therapy for Huntington’s disease’s pivotal results is a new ray of hope for patients disappointed in the past few years. Though one expert is concerned about the communication of the results, which are building false expectations. It is said that few...
